Inozyme Pharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 18, 2024

 

 

INOZYME PHARMA, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware			001-39397	38-4024528
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
321 Summer Street Suite 400
Boston, Massachusetts				02210
(Address of Principal Executive Offices)				(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (857) 330-4340

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.0001 per share		INZY		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

---

Item 5.07 Submission of Matters to a Vote of Security Holders.

At the Company's annual meeting of stockholders held on June 18, 2024, the Company’s stockholders voted on the following proposals:

	1.	The following three nominees were elected to the Board of Directors of the Company as Class I directors, each to serve for a three-year term expiring at the 2027 annual meeting of stockholders. The results of the stockholders’ votes with respect to the election of such Class I directors were as follows:

 

		Votes For		Votes Withheld		Broker Non-Votes
Axel Bolte		47,252,598		422,811		5,662,139
Robert Hopfner		47,593,182		289,978		5,454,388
Edward Mathers		27,708,257		19,965,581		5,663,710

	2.	The appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2024 was ratified. The results of the stockholders’ votes with respect to such ratification were as follows:

Votes For:			53,326,387
Votes Against:			7,653
Votes Abstaining:			3,508
Broker Non-Votes:			—

 

 

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			INOZYME PHARMA, INC.
Date:	June 20, 2024	By:	/s/ Douglas A. Treco
			Name: Douglas A. Treco Title: Chief Executive Officer

 

---